Intratumoral Heterogeneity Determines Discordant Results of Diagnostic Tests for Human Epidermal Growth Factor Receptor (HER) 2 in Gastric Cancer Specimens

Cell Biochemistry and Biophysics

Volumn 62, Issue 1, 2012, Pages 221-228

  Yang, Jiyuan ^a,b   Luo, Hesheng ^a   Li, Yan ^a   Li, Junchuan ^b   Cai, Zhiqiang ^b   Su, Xiaoyan ^b   Dai, Danqing ^b   Du, Wei ^b   Chen, Tingxuan ^b   Chen, Ming ^a,b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b YANGTZE UNIVERSITY   (China)

Author keywords

Fluorescence in situ hybridization; Gastric cancer; Human epidermal growth factor receptor 2; Immunohistochemistry; Intratumoral heterogeneity

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; REPRODUCIBILITY; STOMACH TUMOR;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84855567211     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-011-9286-1     Document Type: Article

References (39)

1. Kelley, J. R., & Duggan, J. M. (2003). Gastric cancer epidemiology and risk factors. Journal of Clinical Epidemiology, 56, 1-9.
2. Roder DM (2002) The epidemiology of gastric cancer. Gastric Cancer. 5 Suppl 1, 5-11.
3. Comella, P., Franco, L., Casaretti, R., de Portu, S., & Menditto, E. (2009). Emerging role of capecitabine in gastric cancer. Pharmacotherapy, 29, 318-330.
4. Gravalos, C., & Jimeno, A. (2008). HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Annals of Oncology, 19, 1523-1529.
5. Wagner, A. D., Grothe, W., Haerting, J., Kleber, G., Grothey, A., & Fleig, W. E. (2006). Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. Journal of Clinical Oncology, 24, 2903-2909.
6. Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., van de Velde, C. J., Nicolson, M., et al. (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine, 355, 11-20.
7. Ohtsu, A. (2008). Chemotherapy for metastatic gastric cancer: past, present, and future. Journal of Gastroenterology, 43, 256-264.
8. Jorgensen, J. T. (2010). Targeted HER2 treatment in advanced gastric cancer. Oncology, 78, 26-33.
9. Cunningham, S. C., Kamangar, F., Kim, M. P., Hammoud, S., Haque, R., Maitra, A., et al. (2005). Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution. Journal of Gastrointestinal Surgery, 9, 718-725.
10. Akiyama, T., Sudo, C., Ogawara, H., Toyoshima, K., & Yamamoto, T. (1986). The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science, 232, 1644-1646.
11. Normanno, N., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., De, L. A., et al. (2005). The ErbB receptors and their ligands in cancer: an overview. Current Drug Targets, 6, 243-257.
12. Hynes, N. E., & Lane, H. A. (2005). ERBB receptors and cancer: The complexity of targeted inhibitors. Nature Reviews Cancer, 5, 341-354.
13. Hudis, C. A. (2007). Trastuzumab: Mechanism of action and use in clinical practice. New England Journal of Medicine, 357, 39-51.
14. Smith, I., Procter, M., Gelber, R. D., Guillaume, S., Feyereislova, A., Dowsett, M., et al. (2007). 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet, 369, 29-36.
15. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine, 344, 783-792.
16. Bang, Y. J., Van, C. E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., et al. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet, 376, 687-697.
17. Croxtall, J. D., & McKeage, K. (2010). Trastuzumab: In HER2-positive metastatic gastric cancer. Drugs, 70, 2259-2267.
18. Sui, W., Ou, M., Chen, J., Wan, Y., Peng, H., Qi, M., et al. (2009). Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for HER2 status in breast cancer. World Journal of Surgical Oncology, 7, 83.
19. Rüschoff, J., Dietel, M., Baretton, G., Arbogast, S., Walch, A., Monges, G., et al. (2010). HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Archiv, 457, 299-307.
20. Vanden Bempt, I., Vanhentenrijk, V., Drijkoningen, M., Wlodarska, I., Vandenberghe, P., & De Wolf-Peeters, C. (2005). Real-time reverse transcription-PCR and fluorescence in situ hybridization are complementary to understand the mechanisms involved in HER2/neu overexpression in human breast carcinomas. Histopathology, 46, 431-441.
21. Bartlett, J. M., & Forsyth, A. (2006). Detection of HER2 gene amplification by fluorescence in situ hybridization in breast cancer. Methods in Molecular Medicine, 120, 309-322.
22. Sauter, G., Lee, J., Bartlett, J. M., Slamon, D. J., & Press, M. F. (2009). Guidelines for human epidermal growth factor receptor 2 testing: Biologic and methodologic considerations. Journal of Clinical Oncology, 27, 1323-1333.
23. Wolff, A. C., Hammond, M. E., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., et al. (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Journal of Clinical Oncology, 25, 118-145.
24. Hofmann, M., Stoss, O., Shi, D., Buttner, R., van de Vijver, M., Kim, W., et al. (2008). Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. Histopathology, 52, 797-805.
25. Brunelli, M., Manfrin, E., Martignoni, G., Miller, K., Remo, A., Reghellin, D., et al. (2009). Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: Evaluation according to ASCO/CAP criteria. American Journal of Clinical Pathology, 131, 678-682.
26. Fukushige, S., Matsubara, K., Yoshida, M., Sasaki, M., Suzuki, T., Semba, K., et al. (1986). Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Molecular and Cellular Biology, 6, 955-958.
27. Takehana, T., Kunitomo, K., Kono, K., Kitahara, F., Iizuka, H., Matsumoto, Y., et al. (2002). Status of c-erbB-2 in gastric adenocarcinoma: A comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. International Journal of Cancer, 98, 833-837.
28. Allgayer, H., Babic, R., Gruetzner, K. U., Tarabichi, A., Schildberg, F. W., & Heiss, M. M. (2000). c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. Journal of Clinical Oncology, 18, 2201-2209.
29. Wang, Y. L., Sheu, B. S., Yang, H. B., Lin, P. W., & Chang, Y. C. (2002). Overexpression of c-erb-B2 proteins in tumor and non-tumor parts of gastric adenocarcinoma-emphasis on its relation to H. pylori infection and clinicohistological characteristics. Hepato-Gastroenterology, 49, 1172-1176.
30. Shun, C. T., Wu, M. S., Lin, J. T., Chen, S. Y., Wang, H. P., Lee, W. J., et al. (1997). Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer. Hepato-Gastroenterology, 44, 604-609.
31. Yano, T., Doi, T., Ohtsu, A., Boku, N., Hashizume, K., Nakanishi, M., et al. (2006). Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncology Reports, 15, 65-71.
32. Kim, M. A., Jung, E. J., Lee, H. S., Lee, H. E., Jeon, Y. K., Yang, H. K., et al. (2007). Evaluation of HER2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Human Pathology, 38, 1386-1393.
33. Yan, B., Yau, E. X., Bte Omar, S. S., Ong, C. W., Pang, B., Yeoh, K. G., et al. (2010). A study of HER2 gene amplification and protein expression in gastric cancer. Journal of Clinical Pathology, 63, 839-842.
34. Barros-Silva, J. D., Leitao, D., Afonso, L., Vieira, J., Dinis-Ribeiro, M., Fragoso, M., et al. (2009). Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. British Journal of Cancer, 100, 487-493.
35. Bang, Y., Chung, J., Xu, J., et al. (2009). Pathological features of advanced gastric cancer (gc): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trail. Journal of Clinical Oncology 27, abstract 4556.
36. Vance, G. H., Barry, T. S., Bloom, K. J., Fitzgibbons, P. L., Hicks, D. G., Jenkins, R. B., et al. (2009). Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Archives of Pathology and Laboratory Medicine, 133, 611-612.
37. Marx, A. H., Tharun, L., Muth, J., Dancau, A. M., Simon, R., Yekebas, E., et al. (2009). HER2 amplification is highly homogenous in gastric cancer. Human Pathology, 40, 769-777.
38. Bilous, M., Osamura, R. Y., Ruschoff, J., van de Vijver, M., Hanna, W., Penault-Llorca, F., et al. (2010). HER2 amplification is highly homogenous in gastric cancer. Human Pathology, 41, 304-305.
39. Grabsch, H., Sivakumar, S., Gray, S., Gabbert, H. E., & Muller, W. (2010). HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series. Cell Oncol., 32, 57-65.